BC Extra | Jan 23, 2020
Politics & Policy

MNCs lead price cuts in China’s second round of centralized procurement

MNC originators took the deepest price cuts in the second round of China’s expanded centralized procurement program for generic and off-patent drugs. A list released Tuesday by China’s Joint Procurement Office showed that 77 winning...
BC Week In Review | Oct 5, 2018
Clinical News

FDA approves Paratek antibiotics

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) received a pair of FDA approvals Oct. 2 for Nuzyra omadacycline and Seysara sarecycline. The agency approved Nuzyra to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure...
BC Extra | Oct 2, 2018
Company News

FDA approves Paratek antibiotics

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) received a pair of FDA approvals Tuesday for Nuzyra omadacycline and Seysara sarecycline. The agency approved Nuzyra to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections...
BC Week In Review | Aug 31, 2018
Clinical News

TB Alliance starts pivotal trial of four-drug regimen

The Global Alliance for TB Drug Development (TB Alliance) began the pivotal Phase IIc SimpliciTB trial evaluating an oral four-drug regimen called BPaMZ to treat tuberculosis. SimpliciTB will compare BPaMZ, which comprises a once-daily combination...
BC Extra | Aug 28, 2018
Clinical News

TB Alliance starts pivotal trial of four-drug regimen

The Global Alliance for TB Drug Development (TB Alliance) began the pivotal Phase IIc SimpliciTB trial evaluating an oral four-drug regimen called BPaMZ to treat tuberculosis. SimpliciTB will compare BPaMZ, which comprises a once-daily combination...
BC Innovations | Aug 8, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Pneumonia; bacterial infection Cell culture and mouse studies identified a methoxyquinolone-based compound that could help treat bacterial pneumonia. Structure-based design, chemical synthesis and testing in bacterial cultures of methoxyquinolone analogs yielded a compound that...
BC Week In Review | May 25, 2018
Clinical News

Nabriva's lefamulin meets in Phase III LEAP 2 trial for CABP

Nabriva Therapeutics plc (NASDAQ:NBRV) reported a higher incidence of GI adverse events in patients who received oral lefamulin (BC-3781) in the Phase III LEAP 2 trial to treat moderate community-acquired bacterial pneumonia (CABP). While the...
BC Extra | May 21, 2018
Clinical News

Nabriva falls on GI safety in second Phase III for CABP

Nabriva Therapeutics plc (NASDAQ:NBRV) lost $0.90 (17%) to $4.53 on Monday after reporting a higher incidence of GI adverse events in patients who received oral lefamulin (BC-3781) in the Phase III LEAP 2 trial to...
BC Week In Review | Feb 2, 2018
Clinical News

Da Volterra's DAV132 meets in Phase I for antibiotic-induced dysbiosis

Da Volterra (Paris, France) reported data from the open-label, French Phase I DAV132-CL-1002 trial in 44 healthy volunteers showing that DAV132 met the primary endpoint by effectively capturing residual moxifloxacin in the colon. Specifically, co-administration...
BC Week In Review | Sep 22, 2017
Clinical News

Nabriva's lefamulin meets in Phase III LEAP 1 trial for CABP

Nabriva Therapeutics plc (NASDAQ:NBRV) reported that IV-to-oral lefamulin (BC-3781) met the FDA- and EMA-defined primary endpoints in the double-blind, international Phase III LEAP 1 trial to treat moderate to severe community-acquired bacterial pneumonia (CABP). Top-line...
Items per page:
1 - 10 of 160